ARMP · Armata Pharmaceuticals, Inc.
$4.56
-0.26 (-5.39%)
At close · Aug 14
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These circumstances raise substantial doubt about the Company’s ability to continue as a going concern. While management believes this plan to raise additional funds will alleviate the conditions that raise substantial doubt, these plans are not entirely within our control and cannot be assessed as being probable of occurring.”View the 10-Q filed Aug 12, 2026
Market Cap
$169.55M
Shares
37.18M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$173.8M
-818.8%
FY2025
Diluted EPS
-$4.80
-439.3%
FY2025
Operating Cash Flow
-$25.76M
+31.4%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $25.59M | $23.72M | $34.43M | $33.77M | $35.02M | $20.02M | $14.44M | $9.82M | $8.37M | $2.88M | $5.68M | $3.99M | $5.81M | $6.47M | |
| $15.24M | $12.41M | $13.18M | $11.65M | $7.44M | $8.28M | $7.97M | $9.27M | $2.52M | $7.59M | $8.41M | $6.71M | $6.85M | $6M | |
| — | — | — | — | — | — | — | — | $31K | $31K | $31K | $31K | $31K | $31K | |
| — | — | $1.33M | $972K | $892K | — | — | — | — | — | — | — | — | — | |
| $46.24M | $41.54M | $47.61M | $45.42M | $42.45M | $28.3M | $22.41M | $19.75M | $17.66M | $16.27M | $23.64M | $10.7M | $14.52M | $12.47M | |
| -$40.7M | -$36.63M | -$42.44M | -$40.89M | -$36.95M | -$23.82M | -$21.59M | -$19.75M | -$17.66M | -$16.16M | -$23.38M | -$10.23M | -$14.11M | -$12.38M | |
| — | — | — | — | $0 | $64K | $628K | $931K | $1.01M | — | $6000 | — | $0 | $233K | |
| $388K | — | — | $179K | $29K | $5000 | $28K | $96K | $245K | — | — | — | — | — | |
| -$151.48M | -$137.17M | $23.52M | -$28.16M | $29K | $667K | -$594K | $273K | $956K | $2.02M | $3.98M | $9.64M | $37.22M | -$52.2M | |
| — | -$173.8M | -$18.92M | -$69.05M | -$36.92K | -$23.16M | -$22.18M | -$19.48M | -$16.7M | -$14.14M | -$19.39M | -$589K | $23.11M | — | |
| — | — | — | — | — | — | — | — | -$328K | -$1.3M | -$556K | -$73K | — | — | |
| -$192.18M | -$173.8M | -$18.92M | -$69.05M | -$36.92M | -$23.16M | -$22.18M | -$19.48M | -$16.7M | -$12.84M | -$18.84M | -$516K | $23.11M | -$64.58M | |
| — | -$173.8M | -$18.92M | -$69.05M | — | — | — | -$19.48M | -$16.7M | -$12.84M | -$24.28M | -$10.79M | $15.76M | -$65.2M | |
| $23.35M | — | — | — | — | — | — | — | — | — | — | — | — | -$57.61M | |
| USD/shares | — | -$4.80 | -$0.52 | -$1.91 | -$1.08 | -$0.96 | -$1.35 | -$2.49 | -$3.59 | -$2.01 | -$24.67 | -$1.99 | $4.21 | -$0.64 |
| USD/shares | — | -$4.80 | -$0.89 | -$1.91 | -$1.08 | -$0.96 | -$1.35 | -$2.55 | -$3.59 | -$2.18 | -$24.67 | -$1.99 | -$2.33 | -$0.64 |
| shares | — | 36.24M | 36.16M | 36.08M | 34.29M | 24.1M | 16.42M | 7.83M | 4.65M | 6.39M | 983.85K | 5.41M | 3.75M | 101.2M |
| shares | — | 36.24M | 59.06M | 36.08M | 34.29M | 24.1M | 16.42M | 8.01M | 4.65M | 6.57M | 983.85K | 5.41M | 5.89M | 101.2M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.35×
EV/EBIT
—
Peer median 9.33×
P/E (TTM)
—
Peer median 9.02×
Peer medians compare against the 311 similar-size Biotechnology companies (of 545 listed).
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Single Reportable Segment | -$36,634,000 | -$42,436,000 | -$40,890,000 |
Key facts
CIK
921114
CUSIP
04216R102
13F (30d)
51 filings
51 filers
Visit website
Investor relations